S&P 500   3,269.96 (-1.21%)
DOW   26,501.60 (-0.59%)
QQQ   269.38 (-2.54%)
AAPL   108.86 (-5.60%)
MSFT   202.47 (-1.10%)
FB   263.11 (-6.31%)
GOOGL   1,616.11 (+3.80%)
AMZN   3,036.15 (-5.45%)
TSLA   388.04 (-5.55%)
NVDA   501.36 (-3.76%)
BABA   304.69 (-2.52%)
CGC   18.78 (+0.00%)
GE   7.42 (+0.68%)
MU   50.34 (-0.28%)
AMD   75.29 (-3.50%)
T   27.02 (+0.97%)
F   7.73 (-2.15%)
ACB   4.05 (-0.98%)
GILD   58.15 (-0.65%)
NIO   30.58 (-4.41%)
NFLX   475.74 (-5.65%)
BA   144.39 (-2.63%)
DIS   121.25 (-0.24%)
S&P 500   3,269.96 (-1.21%)
DOW   26,501.60 (-0.59%)
QQQ   269.38 (-2.54%)
AAPL   108.86 (-5.60%)
MSFT   202.47 (-1.10%)
FB   263.11 (-6.31%)
GOOGL   1,616.11 (+3.80%)
AMZN   3,036.15 (-5.45%)
TSLA   388.04 (-5.55%)
NVDA   501.36 (-3.76%)
BABA   304.69 (-2.52%)
CGC   18.78 (+0.00%)
GE   7.42 (+0.68%)
MU   50.34 (-0.28%)
AMD   75.29 (-3.50%)
T   27.02 (+0.97%)
F   7.73 (-2.15%)
ACB   4.05 (-0.98%)
GILD   58.15 (-0.65%)
NIO   30.58 (-4.41%)
NFLX   475.74 (-5.65%)
BA   144.39 (-2.63%)
DIS   121.25 (-0.24%)
S&P 500   3,269.96 (-1.21%)
DOW   26,501.60 (-0.59%)
QQQ   269.38 (-2.54%)
AAPL   108.86 (-5.60%)
MSFT   202.47 (-1.10%)
FB   263.11 (-6.31%)
GOOGL   1,616.11 (+3.80%)
AMZN   3,036.15 (-5.45%)
TSLA   388.04 (-5.55%)
NVDA   501.36 (-3.76%)
BABA   304.69 (-2.52%)
CGC   18.78 (+0.00%)
GE   7.42 (+0.68%)
MU   50.34 (-0.28%)
AMD   75.29 (-3.50%)
T   27.02 (+0.97%)
F   7.73 (-2.15%)
ACB   4.05 (-0.98%)
GILD   58.15 (-0.65%)
NIO   30.58 (-4.41%)
NFLX   475.74 (-5.65%)
BA   144.39 (-2.63%)
DIS   121.25 (-0.24%)
S&P 500   3,269.96 (-1.21%)
DOW   26,501.60 (-0.59%)
QQQ   269.38 (-2.54%)
AAPL   108.86 (-5.60%)
MSFT   202.47 (-1.10%)
FB   263.11 (-6.31%)
GOOGL   1,616.11 (+3.80%)
AMZN   3,036.15 (-5.45%)
TSLA   388.04 (-5.55%)
NVDA   501.36 (-3.76%)
BABA   304.69 (-2.52%)
CGC   18.78 (+0.00%)
GE   7.42 (+0.68%)
MU   50.34 (-0.28%)
AMD   75.29 (-3.50%)
T   27.02 (+0.97%)
F   7.73 (-2.15%)
ACB   4.05 (-0.98%)
GILD   58.15 (-0.65%)
NIO   30.58 (-4.41%)
NFLX   475.74 (-5.65%)
BA   144.39 (-2.63%)
DIS   121.25 (-0.24%)
Log in
LON:VAL

ValiRx plc (VAL.L) Share Forecast, Price & News

GBX 22.40
-0.10 (-0.44 %)
(As of 10/30/2020 05:27 PM ET)
Add
Compare
Today's Range
21.10
Now: GBX 22.40▼
22.50
50-Day Range
22.15
MA: GBX 29.17▼
59.50
52-Week Range
0.03
Now: GBX 22.40▼
73
Volume1.01 million shs
Average Volume2.75 million shs
Market Capitalization£14.34 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
ValiRx plc, a biotechnology oncology focused company, engages in developing novel therapeutics and associated biomarkers for cancer in the United Kingdom. The company's lead drug candidates include VAL201, an anti-cancer therapeutic that is in Phase I/II trials for the treatment of prostate cancer and other indications of hormone induced unregulated growth, including endometriosis; VAL301, a reformulation of VAL201, which is in pre-clinical development for the treatment of women with endometriosis; and VAL401, a reformulation of generic drug Risperidone, which has completed Phase II clinical trial for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL101, a candidate produced by GeneICE technology platform to modulate BCl2 expression Â- implicated in cancers. ValiRx plc has collaboration agreement with Oncolytika Limited and Black Cat Bio Limited to develop and evaluate BC201 for patients suffering a hyperimmune response to Coronavirus SARS-CoV2 infection. The company was incorporated in 2000 and is based in Hatfield, the United Kingdom.
Read More
ValiRx plc (VAL.L) logo

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 1.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.34 out of 5 stars

Industry, Sector and Symbol

Stock Exchange LON
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolLON:VAL
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.valirx.com
Phone+44-20-30084416
Employees11

Debt

Debt-to-Equity Ratio8.75
Current Ratio0.74
Quick Ratio0.74

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowGBX 0.72 per share
Price / Cash Flow31.07
Book ValueGBX 8.10 per share
Price / Book2.77

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding Shares64,028,300
Market Cap£14.34 million
Next Earnings DateN/A
OptionableNot Optionable
GBX 22.40
-0.10 (-0.44 %)
(As of 10/30/2020 05:27 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VAL News and Ratings via Email

Sign-up to receive the latest news and ratings for VAL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ValiRx plc (VAL.L) (LON:VAL) Frequently Asked Questions

How has ValiRx plc (VAL.L)'s stock been impacted by COVID-19 (Coronavirus)?

ValiRx plc (VAL.L)'s stock was trading at GBX 0.05 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VAL stock has increased by 49,677.8% and is now trading at GBX 22.40.
View which stocks have been most impacted by COVID-19.

How were ValiRx plc (VAL.L)'s earnings last quarter?

ValiRx plc (VAL.L) (LON:VAL) announced its earnings results on Monday, September, 7th. The company reported ($4.43) earnings per share for the quarter.
View ValiRx plc (VAL.L)'s earnings history.

Who are some of ValiRx plc (VAL.L)'s key competitors?

Some companies that are related to ValiRx plc (VAL.L) include Predictive Technology Group (PRED), Navidea Biopharmaceuticals (NAVB), Navidea Biopharmaceuticals (NAVB), Sirona Biochem Corp. (SBM.V) (SBM), Armata Pharmaceuticals (ARMP), Armata Pharmaceuticals (ARMP), Aerpio Pharmaceuticals (ARPO), OptiBiotix Health (OPTI), Cocrystal Pharma (COCP), Cocrystal Pharma (COCP), IXICO plc (IXI.L) (IXI), Helix Biopharma (HBP), Cohbar (CWBR), Cohbar (CWBR) and Microbix Biosystems Inc. (MBX.TO) (MBX).
View all competitors.

What other stocks do shareholders of ValiRx plc (VAL.L) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ValiRx plc (VAL.L) investors own include Petrofac Limited (PFC.L) (PFC), boohoo group plc (BOO.L) (BOO), ReNeuron Group plc (RENE.L) (RENE), Falanx Group (FLX), Solo Oil Plc (SOLO.L) (SOLO), CyanConnode Holdings plc (CYAN.L) (CYAN), IQE plc (IQE.L) (IQE), Lloyds Banking Group (LLOY), Eckoh (ECK) and Sareum Holdings plc (SAR.L) (SAR).

Who are ValiRx plc (VAL.L)'s key executives?

ValiRx plc (VAL.L)'s management team includes the following people:
  • Mr. James Gerry Desler, CFO & Director (Age 64, Pay $52.89k)
  • Mr. Kevin J. Alexander, Sec. & Independent Non-Exec. Director (Age 64, Pay $25.62k)
  • Dr. Suzanne J. Dilly B.Sc., BSc, Ph.D., CEO & Director (Age 42)
  • Mr. Kumar Nawani, Head of Operations
  • Mr. Tarquin Edwards, Head of Investor Relations & Communications
  • Mr. Mark Treharne, Corp. Devel. Mang.

What is ValiRx plc (VAL.L)'s stock symbol?

ValiRx plc (VAL.L) trades on the London Stock Exchange (LON) under the ticker symbol "VAL."

How do I buy shares of ValiRx plc (VAL.L)?

Shares of VAL and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is ValiRx plc (VAL.L)'s stock price today?

One share of VAL stock can currently be purchased for approximately GBX 22.40.

How big of a company is ValiRx plc (VAL.L)?

ValiRx plc (VAL.L) has a market capitalization of £14.34 million. ValiRx plc (VAL.L) employs 11 workers across the globe.

What is ValiRx plc (VAL.L)'s official website?

The official website for ValiRx plc (VAL.L) is www.valirx.com.

How can I contact ValiRx plc (VAL.L)?

ValiRx plc (VAL.L)'s mailing address is 3rd Fl, 16 Upper Woburn Place, LONDON, WC1H 0BS, United Kingdom. The company can be reached via phone at +44-20-30084416.

This page was last updated on 10/30/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.